Actualités et Activités de Actinium Pharmaceuticals
Présence
Actinium Pharmaceuticals fait partie des...
Actinium Pharmaceuticals est une société cotée sous le symbole boursier ATNM (US).
Dirigeants
Voir l'organigramme avec ses 18 principaux dirigeants
Biographies les plus recherchées chez Actinium Pharmaceuticals
- Sandesh Seth, Chairman of the Board and Chief Executive Officer
- David Nicholson, Lead Independent Director
- Richard Steinhart, Director
Changements de dirigeants chez Actinium Pharmaceuticals
- June Almenoff, a rejoint l'entreprise comme Director (publié le 5 novembre 2024).
Créer une alerte
pour suivre les mouvements de dirigeants chez Actinium Pharmaceuticals.
Pharmacie
Actinium Pharmaceuticals a 1 834 concurrents dont Pfizer (Etats—Unis), Sanofi (France) et Eli Lilly (Etats—Unis).
Actualités en fusion/acquisition en Pharmacie.
- Imbria Pharmaceuticals vient d'annoncer une levée de fonds de 58 millions de dollars. (publié le 10 avril 2025).
- Clario a acquis NRx Pharmaceuticals (publié le 18 mars 2025).
- Knight Therapeutics has announced the acquisition of Paladin Labs (publié le 12 mars 2025).
Contacts en Pharmacie
Actualités
Derniers communiqués de presse par Actinium Pharmaceuticals
- Actinium Pharmaceuticals Announces ATNM-400 a Novel Non-PSMA Targeting First in Class Prostate Cancer Radiotherapy Leveraging Actinium-225 :: Actinium Pharmaceuticals, Inc. (ATNM)
- Actinium Pharmaceuticals to Present Business Update at Trump Mar-A-Lago Club Today :: Actinium Pharmaceuticals, Inc. (ATNM)
- Press Releases :: Actinium Pharmaceuticals, Inc. (ATNM)
- Actinium Pharmaceuticals Provides Business Update After Presentation at Trump Mar-A-Lago Club Announcing Novel Non-PSMA Prostate Cancer Radiotherapy ATNM-400 and Outlining Revitalized Clinical Pipeline with 2025 Corporate Objectives :: Actinium Pharmaceut
- Actinium Pharmaceuticals Announces Supply Agreement with Eckert & Ziegler for Ac-225 Radioisotope to Support Comprehensive Development Activities :: Actinium Pharmaceuticals, Inc. (ATNM)
- Actinium Pharmaceuticals to Host KOL Investor Call at 8am ET Today to Highlight Revamped Clinical Programs and Expanded Market Opportunities Including Newly Initiated Actimab-A Solid Tumor Program :: Actinium Pharmaceuticals, Inc. (ATNM)
- Actinium Pharmaceuticals to Host Investor KOL Call with Dr. Ehab Atallah of the Medical College of Wisconsin and Provide a Pipeline Update Highlighting Revamped Clinical Programs and Expanded Market Opportunities for Actimab-A and Iomab-ACT with Clinical
- Actinium Pharmaceuticals Announces Research Collaboration with Memorial Sloan Kettering to Support Further Clinical Expansion of Actimab-A's Backbone Therapy Strategy :: Actinium Pharmaceuticals, Inc. (ATNM)
- Actinium Pharmaceuticals Announces Clinical Trial Program in Solid Tumors Combining Actimab-A with PD-1 Checkpoint Inhibitors KEYTRUDA® and OPDIVO® :: Actinium Pharmaceuticals, Inc. (ATNM)
- Actinium Pharmaceuticals Announces Publication of Actimab-A + CLAG-M Trial Results in Patients with Relapsed or Refractory Acute Myeloid Leukemia in the Peer-Reviewed Journal Leukemia :: Actinium Pharmaceuticals, Inc. (ATNM)
- Voir plus de communiqués de presse Close
Réseaux sociaux à propos de Actinium Pharmaceuticals
- Actinium Pharmaceuticals sur Wikipédia, Google News & Yahoo Finance en 1-click
- Actinium Pharmaceuticals sur LinkedIn, Twitter & YouTube en 1-click
